Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

CAPS Rating: 2 out of 5

The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.


Player Avatar lemapud (< 20) Submitted: 1/22/2007 5:20:24 PM : Outperform Start Price: $7.70 IDRA Score: -100.58

IDERA has cutting edge new science in the field of immunology. They have had their share of followers and detractors over the years, and survived through it all. They have a strong company plan now, good partners, and exciting therapies that will be used to combat aids, cancer, and other human maladies. Above all IDERA has always been an honest, intelligent company that had strived to make a difference in health and science.

Member Avatar zzlangerhans (99.85) Submitted: 5/11/2010 3:36:20 PM
Recs: 0

Wow. I don't know whether to invest in Idera or date Idera.

Featured Broker Partners